cardiovascular disease

One-time CRISPR gene therapy cuts cholesterol ~50% for a full year, trial finds

A single infusion of a CRISPR-based gene-editing therapy produced durable reductions in LDL cholesterol and triglycerides that persisted through one year of follow-up, researchers reported Friday at the European Society of Cardiology Congress 2026 in a presentation simultaneously published in…

Novo Nordisk shares tumble after key heart drug fails late-stage trial

Novo Nordisk announced on Friday that its experimental anti-inflammatory drug ziltivekimab failed to reduce the risk of major adverse cardiovascular events in the Phase 3 ZEUS trial, sending shares of the Danish drugmaker down 10% in premarket trading.